Novartis AG 2013 AR2
The report highlights Novartis' financial and operational performance for the fiscal year 2013, emphasizing its strategic focus on science-based innovation, growth, and productivity. In 2013, the company achieved net sales of USD 57.9 billion and invested USD 9.9 billion in research and development to advance its pipeline, securing three FDA breakthrough therapy designations. Through its corporate responsibility initiatives, Novartis reached over 100 million patients with access-to-healthcare programs valued at USD 2.1 billion. Additionally, the company made progress toward its environmental targets, reducing greenhouse gas emissions by 13.7% compared to 2008 levels.
Company: Novartis AG
Sector: Manufacturing
Country: Switzerland
Year: 2013
Type: AR2
Pages: 282
Novartis AG
The report highlights Novartis' financial and operational performance for the fiscal year 2013, emphasizing its strategic focus on science-based innovation, growth, and productivity. In 2013, the company achieved net sales of USD 57.9 billion and invested USD 9.9 billion in research and development to advance its pipeline, securing three FDA breakthrough therapy designations. Through its corporate responsibility initiatives, Novartis reached over 100 million patients with access-to-healthcare programs valued at USD 2.1 billion. Additionally, the company made progress toward its environmental targets, reducing greenhouse gas emissions by 13.7% compared to 2008 levels.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2013
Reporting Period
Jan 1, 2013 - Dec 31, 2013
Fiscal Year
2013
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
Assurance
Assurance Provider
Assurance Standard
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Total Waste
Women on Board
Women in Management
Employees